Predictors of linear accelerator versus Gamma Knife stereotactic radiosurgery use for brain metastases in the United States
dc.contributor.author | McClelland, Shearwood, III. | |
dc.contributor.author | Degnin, Catherine | |
dc.contributor.author | Chen, Yiyi | |
dc.contributor.author | Watson, Gordon A. | |
dc.contributor.author | Jaboin, Jerry J. | |
dc.contributor.department | Radiation Oncology, School of Medicine | en_US |
dc.date.accessioned | 2022-01-14T20:10:03Z | |
dc.date.available | 2022-01-14T20:10:03Z | |
dc.date.issued | 2019-11 | |
dc.description.abstract | INTRODUCTION Stereotactic radiosurgery (SRS) for brain metastases is predominantly delivered via single-fraction Gamma Knife SRS (GKRS) or linear accelerator (LINAC) in 1–5 fractions. Predictors of SRS modality have been sparsely examined on a nationwide level. METHODS The 2010–2016 National Cancer Database identified brain metastases patients from non-small cell lung cancer throughout the United States (US) having undergone SRS. A multivariable logistic regression model characterized SRS receipt, adjusting for patient age, dose, geographic location of treatment, facility type, and distance from treatment facility. RESULTS A total of 1,760 patients received GKRS, while 1,064 patients received LINAC SRS. Treatment at non-academic facilities was associated with increased LINAC SRS receipt, most prominently in the Midwestern (OR= 6.23; p< 0.001), Northeastern (OR= 4.42; p< 0.001), and Southern US (OR= 1.96;p< 0.001). Administered doses of 18–19 Gy (OR= 1.42;p= 0.025), 20–21 Gy (OR= 1.82;p< 0.001), and 22–24 Gy (OR= 3.11;p< 0.001) were associated with increased LINAC SRS receipt, as was patient location within 20 miles of a radiation treatment facility (OR= 1.27;p= 0.007). CONCLUSIONS Despite Gamma Knife being more prominently used over LINAC for SRS, patients treated at non-academic facilities outside of the Western US were substantially more likely to receive LINAC over Gamma Knife. Patients located in the Midwest were 523% more likely, Northeast 342% more likely, and South 96% more likely to receive LINAC when treated at a non-academic facility. Increasing dose independently predicted LINAC over GKRS, indicating that smaller tumors – particularly those less than two centimeters (consistent with RTOG 90-05 recommendations) – are being treated with LINAC. Finally, patients residing in close proximity to a treatment center were 27% more likely to receive LINAC, likely indicative of the increased geographic accessibility of LINAC compared with GKRS. These findings should result in hypothesis-generating questions to further explore predictors of LINAC versus GKRS. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | McClelland Iii S, Degnin C, Chen Y, Watson GA, Jaboin JJ. Predictors of linear accelerator versus Gamma Knife stereotactic radiosurgery use for brain metastases in the United States. J Radiosurg SBRT. 2020;6(4):263-267 | en_US |
dc.identifier.issn | 1522-8517, 1523-5866 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/27475 | |
dc.language.iso | en | en_US |
dc.publisher | Oxford Academic | en_US |
dc.relation.isversionof | 10.1093/neuonc/noz175.883 | en_US |
dc.relation.journal | Neuro-Oncology | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Stereotactic radiosurgery | en_US |
dc.subject | linear accelerator | en_US |
dc.subject | Gamma Knife | |
dc.subject | brain metastases | |
dc.title | Predictors of linear accelerator versus Gamma Knife stereotactic radiosurgery use for brain metastases in the United States | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6847028/ | en_US |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RTHP-10. PREDICTORS OF LINEAR ACCELERATOR.pdf
- Size:
- 43.01 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: